[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shmuel Kivity, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,68,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641651","impact-of-advanced-crohns-disease-therapies-on-sleep-quality-100641651",false,"NCT07649408","Impact of Advanced Crohn's Disease Therapies on Sleep Quality","Inclusion Criteria:\n\n* Patients with established diagnosis of Crohn's Disease\n* Patients with active inflammation, defined as HBI score ≥ 5 and either CRP\\>5 or stool calprotectin\\>250 mcg\u002Fgr.\n* Patients starting advanced treatment as part of routine medical care (Anti TNFs, vedolizumab, Ustekinumab, IL-23 inhibitors, Jak inhibitors or S1P inhibitors).\n\nExclusion Criteria:\n\n* Inability to give informed consent and complete the study protocol.\n* Pregnant or lactating women\n* Inability or reluctance to follow through with the study protocol, including (but not exclusive) to: questionnaires, wearing the watch while sleeping.\n* Patients diagnosed with UC or indeterminate IBD.\n* Other sleep disorders Obstructive sleep apnea overactive bladder insomnia shift work disorder restless leg syndrome Periodic limb movement of sleep Narcolepsy\n* Use of sleep medication - such as benzodiazepines or cannabis.\n* Recent abdominal surgery - previous 4 weeks.\n* Severe systemic disease - CVD, Kidney, liver - as jugged by physician's discretion.\n* Patients with ileostomy or short bowl syndrome.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","26 Weeks","OBSERVATIONAL","The goal of this observational study is to measure changes in sleep quality before and after starting treatment with advance therapy in adult with Crohn disease. The main question it aims to answer is: what is the association between response to therapy and sleeping patterns? Participants who are about to begin advanced treatment will be asked to wear a Fitbit device before end after treatment initiation to monitor sleep patterns and sleep quality, complete a sleep diary and a sleep quality questionnaire. The follow-up period will last 26 weeks, during which disease severity and response to treatment will be assessed.",[24],"Crohn Disease (CD)",[26,27,28,29],"CD","Fitbit","Sleep qulity","Response to treatment","RECRUITING","2026-06-14",{"date":33,"type":34},"2026-06-16","ACTUAL",{"date":36,"type":34},"2025-08-06",{"date":38,"type":19},"2027-12",{"name":40,"class":41},"Shmuel Kivity, MD","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100643044","individualizing-anti-tnf-therapy-in-patients-with-inflammatory-bowel-disease-100643044","NCT07644117","Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease","Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease: Pre-Treatment Prediction of Immunogenicity and Response. A Prospective Observational Study.","Inclusion Criteria:\n\n* Established IBD: Crohn's disease (CD) or ulcerative colitis (UC)\n* Anti-TNF naïve\n* Clinically active disease (HBI\\>5 for CD, p-MS≥ 3 for UC)\n* Elevated inflammatory indices CRP\\>10 or fecal calprotectin\\>250\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Anti-TNF experienced\n* Unable to complete the study protocol",{"count":51,"type":19},40,"52 Weeks","This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.\n\nParticipants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.",[55,24,56],"IBD (Inflammatory Bowel Disease)","Ulcerative Colitis (UC)",[58,59,29],"IBD","Anti-TNF","2026-06-11",{"date":62,"type":34},"2026-06-12",{"date":64,"type":34},"2025-01-04",{"date":66,"type":19},"2028-12",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100527365","the-assessment-of-infrared-treatment-for-crohns-disease-100527365","NCT06146816","The Assessment of Infrared Treatment for Crohn's Disease","An Exploratory Clinical Trial for the Assessment of Infrared Treatment for Crohn's Disease","Inclusion Criteria:\n\n1. An established Crohn's disease\n2. 18 \\\u003C age \\\u003C 80\n3. No therapy or on constant medicinal regimen throughout the study period: mesalamine at least 6 weeks, or steroids at least 2 weeks, or immunomodulatory drugs at least 12 weeks or biologics at least 12 weeks, medical cannabis at least 2 weeks before the study.\n4. CD patients will be included if their symptoms score \\>4 on the Harvey-Bradshaw index (HBI) score and\u002For fecal calprotectin level \\> 150 ug\u002Fgr.\n\nExclusion Criteria:\n\n1. BMI greater than 30 Kg\u002Fm2\n2. Any proven current infection such as Clostridioides difficile infection, positive stool culture, or parasites.\n3. Inability to sign informed consent and complete study protocol\n4. Pregnancy\n5. Subjects with chronic conditions such as cancer, organ transplant subjects, advanced kidney or liver disease, systemic inflammatory conditions other than IBD.\n6. Presence of abscess and cysts in the liver\u002F kidneys or pancreas\n7. Evidence of an abdominal abscess or entero-enteric fistula.\n8. More than one CD luminal surgery or a small bowel length \\\u003C 1.5 meter","80 Years",{"count":51,"type":19},"INTERVENTIONAL",[79],"NA","The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients.\n\nThe main questions it aims to answer are:\n\n1. Is infrared therapy safe for treating Crohn's disease patients?\n2. Is infrared therapy effective for treating Crohn's disease?\n\nParticipants will be asked to attend 10 treatments of fIR therapy, provide stool and blood samples and answer questionnaires.\n\nResearchers will compare between 4 treatments: three intensities of fIR therapy and placebo treatment to explore which intensity is most effective for treating Crohn's disease.",[58,82,83],"Inflammatory Bowel Diseases","Crohn Disease",[85,86],"inflammation","Infra-red","2026-02-22",{"date":89,"type":34},"2026-02-24",{"date":91,"type":34},"2023-09-12",{"date":93,"type":19},"2028-01",{"name":40,"class":41},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":77,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":42},"100586597","abdominally-targeted-management-exercises-for-crohns-disease-patients-tame-cd-100586597","NCT06917443","Abdominally Targeted Management Exercises for Crohn's Disease Patients (TAME-CD)","Inclusion Criteria:\n\n* Patients with no treatment or on constant medicinal therapy, expected to remain constant: mesalamine for at least 6 weeks, steroids at least 2 weeks (≤20mg prednisone or budesonide ≤6mg), immunomodulatory at least 12 weeks or biologics\u002F small molecules for at least 12 weeks therapy. Patients who initiate the study on steroids will remain on a constant dose throughout the study.\n* If patients stopped therapy prior to the study then they should be at least 2 weeks from stopping steroids or 5ASA, or 4 weeks from stopping small molecules, 8 weeks from stopping biologics, or 12 weeks from stopping thiopurines.\n* CD patients will be included if their symptoms score \\>4 and ≤15 on the HBI score\n* Fecal calprotectin\\>150ug\u002Fgr or evidence of an active disease per IUS defined as increased blood flow (modified Limberg score\\>0) or thickness of bowel wall\\>3mm\n\nExclusion Criteria:\n\n* Inability to commit for performing at least 10-15 minutes of exercise, 6 times a week.\n* Lack of availability or capability to use a computer\u002F internet.\n* Any proven current infection such as, fever, active abscess, Clostridioides difficile infection, positive stool culture, or parasite in patients with chronic diarrhea.\n* Inability to sign informed consent and\u002F or complete the study protocol.\n* Incompetent individuals who are unable to provide informed consent.\n* Planed pregnancy or pregnancy- up to 3 months post labor.\n* Subjects with chronic conditions such as active arthritis, cancer (within the previous 5 years, not including BCC, SCC), organ transplant subjects, advanced kidney or liver disease, or systemic inflammatory conditions other than IBD.\n* Patients who underwent surgery in the previous 3 months, had more than 1 surgery of intestinal resection, patients with ileostomy, pouch or patients with short bowel (small intestine\\\u003C1.5 meter).\n* Patients with a significant abdominal wall hernia, unless received a written confirmation from a treating surgeon.\n* Active peri-anal disease (fistula, abscess, fissure), stricturing or penetrating disease\n* Active extra-intestinal manifestations (not excluded are- oral aphthae and peripheral arthralgia without arthritis)\n* Patients on total parenteral nutrition (TPN) or on exclusive enteral nutrition (EEN).\n* Probiotics or antibiotics in the 15 days prior to enrollment or during the study period.","60 Years",{"count":103,"type":19},42,[79],"The goal of this clinical trial is to learn if abdominally targeted exercises can assist to manage disease activity in Crohn disease (CD) patients.\n\nThe main questions it aims to answer are:\n\nDoes abdominally targeted exercises can improve the quality of life of CD patients.\n\nDoes abdominally targeted exercises positively influence clinical and biological responses in CD patients.\n\nResearchers will compare performing sets of special physical exercises designed for CD patients, compared to a control set of exercises (\"generic\" physical activity) to see if exercises designed for CD can result in an improved quality of life, in CD patients suffering from mild to moderate disease activity.\n\nParticipants will:\n\n* Perform physical exercises designed for CD or control set of exercises every day for 8 weeks.\n* Visit the clinic once every 4 weeks for doctor visit, blood and stool test and filling out questionnaires.",[24,55],[108,109,110],"physical exercise","Crohn's disease","randomized trial","NOT_YET_RECRUITING","2025-03-31",{"date":114,"type":34},"2025-04-08",{"date":116,"type":19},"2025-04",{"date":118,"type":19},"2029-08",{"name":40,"class":41},""]